Physician profile

Li W Cui

Emergency Medicine · Monterey Park, CA

NPI 1093193575

$1,452.34

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$353.62

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $302.00 2021-2023 Dalvance, Teflaro, Avycaz
Genentech USA, INC. $127.90 2020
Takeda Pharmaceuticals U.S.A., INC. $125.00 2020
Merck Sharp & Dohme LLC $125.00 2020
Epizyme, INC. $125.00 2021
Lilly USA, LLC $124.83 2022
Celgene Corporation $122.00 2020
Genzyme Corporation $121.83 2021
Astrazeneca Pharmaceuticals LP $121.15 2024 Andexxa
Alexion Pharmaceuticals, INC. $105.62 2019
Glaxosmithkline, LLC. $52.01 2023 Trelegy Ellipta

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Li W Cui

$1,452.34

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/7223131/li-w-cui

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.